Nhọpụta ọgwụ nwa mgbei ọhụrụ maka ọgwụgwọ nke Lymphoma follicular

CASI Pharmaceuticals, Inc., ụlọ ọrụ US biopharmaceutical lekwasịrị anya n'ịzụlite na ịzụ ahịa ọgwụgwọ ọhụrụ na ngwaahịa ọgwụ, kwupụtara taa, na US Food and Drug Administration (FDA) enyela onye mmekọ ya BioInvent International AB, maka Orphan Drug Designation (ODD). BI-1206, ihe mgbochi mgbochi FcyRllB nyocha, maka ọgwụgwọ nke lymphoma follicular (FL), ụdị kachasị nke lymphoma Non-Hodgkin na-eto ngwa ngwa (NHL).

Print Friendly, PDF & Email

BI-1206 bụ onye ndoro-ndoro ochichi ọgwụ BioInvent na a na-enyocha ya ugbu a n'ule abụọ nke 1/2. Otu na-enyocha njikọ BI-1206 na rituximab maka ọgwụgwọ nke lymphoma na-abụghị Hodgkin, nke gụnyere ndị ọrịa nwere FL, MCL na lymphoma mpaghara mpaghara (MZL) ndị laghachiri azụ ma ọ bụ na-agbagha na rituximab. Ọnwụnwa nke abụọ nke 1/2 na-enyocha BI-1206 yana ngwakọta mgbochi PD1 ọgwụgwọ Keytruda® (pembrolizumab) na etuto siri ike.

Dr. Wei-Wu He, onye isi oche CASI, na CEO kwuru, "BioInvent na-aga n'ihu na-enwe ọganihu na mmepe na usoro nhazi maka BI-1206. Nkwenye CTA na China na Disemba 2021 yana aha FDA Orphan Drug Design na nso nso a gosipụtara ikike siri ike nke ọgwụ mgbochi mbụ na klaasị. CASI nwere ikike azụmahịa China nke BI-1026, ndị otu anyị na-akwado maka ọmụmụ ụlọ ọgwụ China. CASI na BioInvent bụ ndị mmekọ enweghị nkebi ma nwee ebumnuche ọ bụla iji rite uru ndị ọrịa nwere teknụzụ ọgwụ ọhụrụ.

Print Friendly, PDF & Email

Akụkọ ndi ozo

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment